RTOG launches phase III glioblastoma research
The Radiation Therapy Oncology Group has begun the last leg of a trial assessing temozolomide (Temodar) and radiotherapy plus bevacizumab (Avastin) for newly diagnosed glioblastoma tumors.
The Radiation Therapy Oncology Group has begun the last leg of a trial assessing temozolomide (Temodar) and radiotherapy plus bevacizumab (Avastin) for newly diagnosed glioblastoma tumors.
Patients enrolled in RTOG 0825 will receive standard therapy of radiation and daily temozolomide for three weeks. Patients will then be stratified by MGMT methylation status and molecular profile to receive either standard therapy plus bevacizumab, or a continuation of their standard therapy plus placebo.
RTOG investigators will examine progression-free and overall survival rates, tumor molecular profiles for prognostic factors, neurocognitive function, health-related quality of life, patient-reported outcomes, and treatment side effects.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
